Avacta (AVCT) is a pre-clinical biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology, which continues to dominate the drug industry, despite its limitations. The significant technical and commercial benefits of Affimers is being recognised though increased corporate interest, on-going evaluations, and deal flow. The successful research collaboration with Fit Biotech provides evidence for the feasibility of using Affimer gene delivery in vivo. This represents an additional opportunity for Avacta to develop and partner Affimers as therapeutics.
If you'd like to be introduced to the team at Avacta Group plc, get in touch.Request a meeting